Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Trump Administration Plans Chip Tariff Exemptions for Big Tech Amid AI Data Center Push 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
CLEVELAND, Feb. 15, 2018 -- IMARC Research, a contract research organization based in Strongsville, Ohio, recently expanded its footprint in the medical device market by opening a new office in Minnetonka, Minn. The new office, located at 12301 Whitewater Drive, Suite 125, will continue to be managed by IMARC Senior Clinical Research Specialist Jim Moat.
IMARC opened its first Minneapolis office in the area in 2016. Having a second location continues IMARC’s office-based model, while providing increased flexibility for travel throughout the US and Canada. The move to a new office not only allows room for more staff, it will give the team space to host meetings with clients and potential clients.
The new office underscores IMARC’s continued growth and commitment to ensuring compliance for medical device research.
“Minneapolis is a strong medical device market, so this new location will allow us to better serve our current clients and develop exciting new partnerships,” IMARC CEO and President Sandra Maddock said. “We are eager to assist in advancing clinical research by bringing cost-effective monitoring, managing data safety monitoring boards and clinical events committees, auditing, training, project management and other services closer to home for researchers in this area.”
Moat is a Certified Clinical Research Associate with more than 26 years of experience in medical device product development, with expertise in cardiology, obesity, orthopedic and stroke projects.
About IMARC Research:
A privately held company located in Strongsville, Ohio, IMARC assists the clinical research community in the pursuit of FDA and worldwide approvals. IMARC is a medical device CRO whose effectiveness is built on our commitment to human subject protection and our dedication to ensuring study compliance in our partnership with clients. IMARC’s approach – based solidly in both U.S. and international regulations – results in the support, proof and assurance researchers seek to overcome chaos caused by complexity, while achieving compliance through consistency. Providing committed, competent and confident consultation is how IMARC sets the highest standards for site outcomes and study partnerships.
More information is available at http://www.imarcresearch.com.
Media Contact
John Lehmann
Director of Business Development
440-801-1540, ext. 209
[email protected]
